Volume 30, Number 8—August 2024
Dispatch
Hepatitis B Virus Reactivation after Switch to Cabotegravir/Rilpivirine in Patient with Low Hepatitis B Surface Antibody
, Ayako Sedohara1, Kotaro Arizono, Kazuaki Takahashi, Amato Otani, Yoshiaki Kanno, Makoto Saito, Michiko Koga, and Hiroshi Yotsuyanagi
Table 1
Laboratory values over time of a person in Japan with HIV after diagnosis of an acute HBV infection, from diagnosis to 12 years*
| Category | Time from HBV diagnosis |
|||||||
|---|---|---|---|---|---|---|---|---|
| 0 mo | 1 mo | 3 mo | 9 mo | 5 y | 6 y | 8 y | 12 y | |
| ART regimen |
NA |
TDF/FTC+LPV/RTV |
TDF/FTC |
TDF/FTC |
TDF/FTC |
TDF/FTC |
TDF/FTC |
B/F/TAF |
| Laboratory values | ||||||||
| Anti-HBs, IU/mL† | 20.8 | 0.00 | N/A | 2.03 | N/A | 18.6 | 8.55 | 9.34 |
| HBsAg, mIU/mL‡ | 119,533 | 68,065 | 552 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Anti-HBe, inhibition %§ | Negative | Negative | Negative | Negative | Negative | NA | NA | NA |
| HBeAg, S/CO¶ | 1,840 | 1,290 | 2.5 | Negative | Negative | NA | NA | NA |
| HBV DNA, log copies/mL | >8.8 | 6.8 | 3.8 | ND | ND | ND | NA | ND |
| ALT, U/L | 418 | 937 | 8 | 17 | 23 | 17 | 57 | 66 |
| Total bilirubin, mg/dL | 0.3 | 0.5 | 0.5 | 0.5 | 0.7 | 0.3 | 0.4 | 0.4 |
| HBcrAg, log U/mL# | NA | NA | NA | NA | NA | NA | NA | Negative |
*ALT, alanine aminotransferase; anti-HBe, hepatitis B e-antibody; anti-HBs, hepatitis B surface antibody; ART, antiretroviral therapy; B/F/TAF, bictegravir/emtricitabine/tenofovir alafenamide; HBcrAg, hepatitis B core-related antigen; HBeAg, hepatitis B e-antigen; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; LPV/RTV, lopinavir/ritonavir; mIU, milli-IU; NA, not applicable; ND, not detected; RPV, rilpivirine; S/CO, signal-to-cutoff ratio; TDF/FTC, tenofovir disoproxil fumarate/emtricitabine. †Cutoff value 10 IU/mL. ‡Cutoff value 10 mIU/mL. §Cutoff value 50% inhibition. ¶Cutoff value 1.0 S/CO. #Cutoff value 3.0 log U/mL.
1These first authors contributed equally to this article.